EdgeMarket › What Vivo Capital, Llc reported owning
What Vivo Capital, Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
1.2BPositions
46Quarter
2026-03-31Shown below
46largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| ERAS Erasca, Inc. | 196.6M | 16.3% | 12.2M | 17.63 | +1107.5% |
| PRAX Praxis Precision Medicines, Inc. | 109.2M | 9.1% | 338.9K | 375.94 | +730.8% |
| unmapped CUSIP 880881107 | 70.4M | 5.8% | 1.3M | — | — |
| TRVI Trevi Therapeutics, Inc. | 60.8M | 5.1% | 5.1M | 17.96 | +142.0% |
| DBVT DBV Technologies S.A. | 55.7M | 4.6% | 2.7M | 14.55 | +48.5% |
| CMPX Compass Therapeutics, Inc. | 50.5M | 4.2% | 9.5M | 2.40 | -13.7% |
| TNGX Tango Therapeutics, Inc. | 45.1M | 3.7% | 2.2M | 23.88 | +253.8% |
| SABS SAB Biotherapeutics, Inc. | 43.7M | 3.6% | 11.4M | 3.78 | +88.1% |
| CRVS Corvus Pharmaceuticals, Inc. | 41.0M | 3.4% | 2.8M | 14.46 | +178.6% |
| DRUG BRIGHT MINDS BIOSCIENCES INC. | 40.7M | 3.4% | 557.2K | 77.42 | +80.0% |
| SVA SINOVAC BIOTECH LTD | 38.2M | 3.2% | 5.9M | 6.47 | +0.0% |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 29.7M | 2.5% | 354.0K | 111.10 | +374.4% |
| DYN Dyne Therapeutics, Inc. | 28.2M | 2.3% | 1.6M | 26.10 | +118.0% |
| ABVX Abivax S.A. | 26.7M | 2.2% | 239.5K | 114.95 | +59.9% |
| NERV Minerva Neurosciences, Inc. | 26.0M | 2.2% | 4.3M | 4.84 | +110.7% |
| ACRS Aclaris Therapeutics, Inc. | 25.0M | 2.1% | 6.7M | 6.41 | +254.1% |
| ORIC Oric Pharmaceuticals, Inc. | 23.4M | 1.9% | 1.8M | 14.20 | +49.3% |
| ANRO Alto Neuroscience, Inc. | 23.3M | 1.9% | 1.0M | 34.28 | +899.4% |
| FTH Faeth Therapeutics, Inc. | 22.8M | 1.9% | 722.0K | 32.00 | +302.1% |
| AVBP ArriVent BioPharma, Inc. | 20.4M | 1.7% | 885.9K | 29.12 | +51.1% |
| LBRX LB PHARMACEUTICALS INC | 19.7M | 1.6% | 800.0K | 47.62 | — |
| MANE Veradermics, Inc | 18.9M | 1.6% | 300.0K | 102.82 | — |
| CAMP Camp4 Therapeutics Corp | 18.7M | 1.6% | 4.2M | 4.48 | +190.9% |
| MLTX MoonLake Immunotherapeutics | 18.6M | 1.5% | 1.0M | 15.76 | -70.9% |
| DSGN Design Therapeutics, Inc. | 17.2M | 1.4% | 1.6M | 14.99 | +212.9% |
| COGT Cogent Biosciences, Inc. | 16.3M | 1.4% | 422.3K | 36.73 | +209.6% |
| GERN GERON CORP | 12.9M | 1.1% | 8.7M | 1.52 | +9.4% |
| UNCY Unicycive Therapeutics, Inc. | 11.8M | 1.0% | 1.8M | 5.63 | +37.7% |
| ANTX AN2 Therapeutics, Inc. | 10.8M | 0.9% | 3.2M | 5.81 | +418.8% |
| OLMA Olema Pharmaceuticals, Inc. | 10.0M | 0.8% | 671.8K | 10.69 | +96.1% |
| unmapped CUSIP 834203309 | 9.9M | 0.8% | 294.9K | — | — |
| EPRX EUPRAXIA PHARMACEUTICALS INC. | 9.8M | 0.8% | 1.4M | 6.73 | +27.1% |
| OKUR OnKure Therapeutics, Inc. | 8.0M | 0.7% | 1.9M | 3.94 | +44.3% |
| SRZN Surrozen, Inc./DE | 7.6M | 0.6% | 260.0K | 23.99 | +108.6% |
| ALXO ALX ONCOLOGY HOLDINGS INC | 6.4M | 0.5% | 3.2M | 2.04 | +145.2% |
| MNPR Monopar Therapeutics | 5.0M | 0.4% | 90.5K | 107.72 | +226.4% |
| MSLE Satellos Bioscience Inc. | 4.6M | 0.4% | 813.7K | 10.01 | — |
| PEPG PepGen Inc. | 4.1M | 0.3% | 2.3M | 3.14 | +155.3% |
| SERA SERA PROGNOSTICS, INC. | 3.4M | 0.3% | 1.7M | 2.14 | -4.9% |
| TENX TENAX THERAPEUTICS, INC. | 3.3M | 0.3% | 208.3K | 1.75 | -70.7% |
| VRDN Viridian Therapeutics, Inc.\DE | 3.3M | 0.3% | 166.3K | 24.29 | +33.9% |
| TIL Instil Bio, Inc. | 2.4M | 0.2% | 292.7K | 7.58 | -70.1% |
| KTTA Pasithea Therapeutics Corp. | 1.6M | 0.1% | 2.1M | 0.54 | -23.5% |
| CMPS COMPASS Pathways plc | 1.1M | 0.1% | 200.0K | 13.33 | +226.7% |
| unmapped CUSIP 097702203 | 292.6K | 0.0% | 72.4K | — | — |
| DTIL PRECISION BIOSCIENCES INC | 25.7K | 0.0% | 4.7K | 8.85 | +89.9% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →